Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|March 19, 2024
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trialVikas Gupta, Stephen Oh, Timothy Devos, et al.
Cell Reports. Medicine|February 1, 2025
An integrative multiparametric approach stratifies putative distinct phenotypes of blast phase chronic myelomonocytic leukemiaKristian Gurashi, Yu-Hung Wang, Fabio M R Amaral, et al.
Journal of Medicinal Chemistry|January 10, 2017
Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo StudiesNiall Igoe, Elliott D Bayle, Oleg Fedorov, et al.
The Lancet. Haematology|June 2, 2024
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding studyOlga Salamero, Antonieta Molero, José Antonio Pérez-Simón, et al.
British Journal of Haematology|February 6, 2023
A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemiaYu-Hung Wang, Chi-Yuan Yao, Chien-Chin Lin, et al.
Therapeutic Advances in Hematology|April 4, 2022
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK studyAdam J Mead, Nauman M Butt, Waseem Nagi, et al.
Cancer Cell|March 6, 2018
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute LeukemiaTamara Maes, Cristina Mascaró, Iñigo Tirapu, et al.
Cell Reports|March 29, 2018
Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid LeukemiaAlba Maiques-Diaz, Gary J Spencer, James T Lynch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2022
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and EfficacyClaire N Harrison, Jacqueline S Garcia, Tim C P Somervaille, et al.
American Journal of Hematology|April 13, 2020
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genesJuliana Schwaab, Nicole Naumann, Johannes Luebke, et al.
Pageof 8